Nativ Segev
Follow
Get notifications in MyBN when activity occurs.
Nativ Segev
Nativ Segev is a co-founder of MGC Pharmaceuticals and its managing director. Mr Segev was chief executive of Israel’s second largest licensed medical cannabis company, Cann Pharmaceuticals, known as Better Cannabis and led it from startup through to a large private equity investment. He was also leading the medical cannabis regulation in Israel and the Czech Republic, alongside with developing new medical treatments and spearheading the discovery of new strains.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 91st | Botanix Pharmaceuticals | 100% | 43% |
| 335th | MGC Pharmaceuticals | 26% | -22% |
| 840th | HITIQ | -7% | |
| 1094th | rent.com.au | -25% | -13% |
| 1095th | Adisyn | -25% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 125th |  | MGC Pharmaceuticals | $4.2m |
| 132nd | | Botanix Pharmaceuticals | $3.8m |
| 135th |  | HITIQ | $3.2m |
| 137th |  | Adisyn | $2.9m |
| 138th | | rent.com.au | $2.8m |
201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEWS: Tagged in Board Moves May 31 to June 2, 2023 | 07 Jun 2023 |
| NEW ROLE: Managing Director, MGC Pharmaceuticals | 01 Sep 2020 |
| REMUNERATION UPDATE: Co-Founder, Executive Director & Head of Business Strategy since 2018, MGC Pharmaceuticals | 24 Aug 2020 |
| REMUNERATION UPDATE: Co-Founder, Executive Director & Head of Business Strategy since 2018, MGC Pharmaceuticals | 30 Jun 2020 |
News Articles
Related Information
Positions - Previous
| Position | Company | Year | Company's current rank |
|---|---|---|---|
| Co-Founder, Executive Director & Head of Business Strategy since 2018 | | 2015 - 2023 | 125 |
| Managing Director | | 2015 - 2018 | 125 |
Directors Interests
| Company | Date | Transaction type | Number of shares | Price per share | Transaction value | Nature of change |
|---|---|---|---|---|---|---|
| MGC Pharmaceuticals | 05 May 2023 | Other | 1,050,000 | OtherAs advised by the company: 600,000 Performance Rights, AS per announcement on 05-05-2023 | ||
| MGC Pharmaceuticals | 21 Feb 2019 | Other | 20,000,000 | OtherAs advised by the company: Ordinary Share issued on expiry and conversion of Performance Shares. | ||
| MGC Pharmaceuticals | 21 Feb 2019 | Issued | 1 | OtherAs advised by the company: Ordinary Share issued on expiry and conversion of Performance Shares. | ||
| MGC Pharmaceuticals | 08 Feb 2019 | Bought | 500,000 | $0.04 | $20,000 | On-market trade |
| MGC Pharmaceuticals | 18 May 2018 | Other | 40,000,000 | OtherOff-market transfer |
Powered by Morningstar ®
Equity Capital Markets Deals
| Date | Company | Transaction Type | Total Value | |
|---|---|---|---|---|
| 17/03/17 | MGC Pharmaceuticals | Placement | $10.0m | >> |
| 20/05/16 | MGC Pharmaceuticals | Placement + entitlement offer | $7.5m | >> |
Mergers & Acquisitions Deals
| Announced | Bidder | Target | Transaction Type | Total Value | |
|---|---|---|---|---|---|
| 18/05/15 | Erin Resources | MGC Pharmaceuticals | Reverse Takeover | $1.7m | >> |
